RxDoctor Payments Data

Martin Stone, MD

Internal Medicine · Coral Springs, FLNPI 1639197247

Payments from drug & device makers

$1,236in general payments, 2019–2025

Across 54 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$381
  • Amarin Pharma, Inc.$287
  • Boehringer Ingelheim$120
  • Novo Nordisk$99
  • Lilly USA, LLC$81
  • Aytu Biopharma, Inc.$64
  • plus $204 from 6 others

What the payments were for

  • Food & beverage$1,236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,236 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,852
Medicare patients
114
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$73,287
KerendiaFinerenone37$52,244
EliquisApixaban32$44,147
MounjaroTirzepatide35$43,779
JardianceEmpagliflozin33$43,390
Repatha SureclickEvolocumab25$21,923
XareltoRivaroxaban25$18,815
JanuviaSitagliptin Phosphate27$17,870
VascepaIcosapent Ethyl18$12,582
Rosuvastatin Calcium286$4,310
Losartan Potassium286$2,792
Levothyroxine Sodium155$2,000
Metoprolol Succinate68$1,538
Amlodipine Besylate183$1,469
Atorvastatin Calcium133$1,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$99$73,28767 claims
BayerKerendia$381$52,24437 claims
PfizerEliquis$43$44,14732 claims
Lilly USA, LLCMounjaro$81$43,77935 claims
Boehringer IngelheimJardiance$120$43,39033 claims
Johnson & JohnsonXarelto$26$18,81525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →